Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $1.7 million.

  • Ocular Therapeutix's Other Non Operating Income changed N/A to $1.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29000.0, marking a year-over-year increase of 10010.38%. This contributed to the annual value of $29000.0 for FY2025, which is 10010.38% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Other Non Operating Income stood at $1.7 million.
  • Ocular Therapeutix's 5-year Other Non Operating Income high stood at $25.0 million for Q1 2021, and its period low was -$62.2 million during Q4 2021.
  • In the last 5 years, Ocular Therapeutix's Other Non Operating Income had a median value of $1.1 million in 2023 and averaged -$191200.0.
  • As far as peak fluctuations go, Ocular Therapeutix's Other Non Operating Income skyrocketed by 141890000.0% in 2023, and later plummeted by 279490000.0% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Other Non Operating Income stood at -$62.2 million in 2021, then skyrocketed by 100.0% to $1000.0 in 2022, then skyrocketed by 1418900.0% to $14.2 million in 2023, then crashed by 296.97% to -$28.0 million in 2024, then surged by 106.24% to $1.7 million in 2025.
  • Its Other Non Operating Income was $1.7 million in Q4 2025, compared to -$938000.0 in Q3 2025 and -$172000.0 in Q2 2025.